Burcon posts Q1 loss as company cites ongoing commercialization, scale-up efforts and funding needs

• For the three months ended June 30, 2026, net loss widened to CAD 3.8 million from CAD 3.5 million.
• Operating cash outflow improved to CAD 2.4 million from CAD 2.7 million, despite continued losses.
• Accumulated deficit reached CAD 168.3 million; working capital remained negative at CAD 11.2 million.
• Commercial production and sales continued at its Protein Production Facility for pea, canola, and fava proteins.
• Solatein sunflower protein stayed at pilot scale; commercialization at the facility targeted for calendar 2027.
• Liquidity actions included a CAD 1.4 million loan received subsequent to quarter-end; convertible notes offering launched for up to CAD 8.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burcon NutraScience Corporation published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.